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Aristolochia trilobata L. is an aromatic plant, popularly known as „mil-homens‟, and its 
essential oil is generally used to treat colic, diarrhea, and dysentery disorders. We evaluated 
the antinociceptive effect of A. trilobata stem essential oil (EO) and of its major compound, 
the (R)-(-)-6-methyl-5-hepten-2-yl acetate (sulcatyl acetate: SA), using acetic acid (0.65%)-
induced writhing response and formalin -induced (20 μl of 2,5%) nociceptive behavior in 
mice. We also evaluated the EO and SA effect on motor coordination, using the rota-rod 
apparatus. EO (25, 50 and 100 mg/kg) or SA (25 and 50 mg/kg) reduced nociceptive 
behavior in the writhing test (p < 0.001). EO (100 mg/kg) and SA (25 and 50 mg/kg) 
decreased the nociception on first phase of formalin test (p < 0.05). On second phase, EO 
(25: p < 0.01; 50: p < 0.05 and 100 mg/kg: p < 0.001) and SA (25 and 50 mg/kg; p < 0.001) 
reduced the nociceptive response induced by formalin. EO and SA were not able to cause 
changes in the motor coordination of animals. Together, our results suggest that the EO has 
an analgesic profile and SA seems to be one of the active compounds in this effect. 
 











Pain is defined by the International Association for the Study of Pain (IASP) as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage”(Bogduk and Merskey, 1994). It has the function of  protecting the organism from 
noxious stimuli (Loeser and Treede, 2008). However, sometimes its etiology is 
heterogeneous and the underlying pathophysiology mechanisms are complex, making 
treatment difficult and interfering with the quality of life for people with these pain syndromes 
(Batista et al., 2010). Besides, the wide range of interindividual variability in the perception of 
pain makes the management of pain a major challenge for medicine (Kissin, 2010). 
Natural products emerge as interesting therapeutic resources for the development of 
new drugs for the management of certain painful states (McCurdy and Scully, 2005). The 
search for new chemical entities as therapeutic alternatives for pain or inflammatory 
conditions has constantly progressed (Guimarães et al., 2014, 2013) and presents the 
medicinal plants as the major source (Brito et al., 2013; Lima et al., 2013; Paula-Freire et al., 
2013; Quintans et al., 2013) 
Aristolochia trilobata L. (Aristolochiaceae), popularly known as „mil-homens‟, is found 
from Central America down to South America, having various applications in folk medicine 
(Heinrich et al., 2009). A. trilobata is used by humans to treat stomachaches, colic, 
poisoning, diabetes and also for skin affections (Lans, 2007; Sosa et al., 2002). There are 
few pharmacological data on this plant species. Previous studies have shown that a 
chloroform extract of A. trilobata leaves had antiphlogistic potency close to that of the non-
steroidal anti-inflammatory drug indomethacin (Sosa et al., 2002). 
Considering the antinociceptive potential of essential oils and their constituents and 
the absence of publications demonstrating the antinociceptive effect of A. trilobata, this study 
evaluates the antinociceptive property of stem essential oil (EO) of A. trilobata and its major 
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compound, 6-methyl-5-hepten-2yl acetate (sulcatyl acetate, SA), in animal models of 
nociception. 
 
Material and methods 
 
Plant material  
A. trilobata were collected in Estância-SE/Brazil (satellite positioning: S 11° 14' 22.4'' and W 
037° 25' 00.5''), during October 2011. The voucher specimen was deposited in the 
Herbarium of the Federal University of Sergipe and identified as A. trilobata with voucher 
ASE 23.161. Dry stem A. trilobata was cut into small pieces and crushed in a four-knife mill 
(Marconi®, model MA680). 
 
Essential oil extracted and isolation of sulcatyl acetate  
 The essential oil from 200 g of stem was obtained through hydrodistillation (1500 ml of 
distilled water) for 3 h using a Clevenger-type apparatus. The oil was physically separated 
from the water, dried over anhydrous sodium sulphate and filtered. Samples of the oil were 
transferred to amber glass bottles and stored in a freezer until the GC analysis. The 
distillations were performed in triplicate. Main compounds were isolated through preparative 
thin layer chromatography (TLC), according to Santos et al. (2014). 
 
Chemicals 
Acetic acid, Tween 80, formalin were purchased from Sigma (USA). Morphine, acetylsalicylic 
acid and diazepam were purchased from União Química (Brazil). Sulcatyl acetate was 
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solubilized in saline + 0.2% of Tween 80. Morphine, acetylsalicylic acid and diazepam were 
solubilized in saline. 
 
Animals 
 ale Swiss mice (2 -34 g) were o tained from the  entral Animal  are of the  ederal 
 niversity of Sergipe (S o  rist v o,  razil). Animals were randomly assigned to groups 
and maintained in plastic boxes at controlled room temperature (22 ± 2°C) with free access 
to food and water, under a 12 h light/dark cycle. All the experimental procedures were 
carried out during the light period of the day (08:00 a.m. to 04:00 p.m.) and complied with the 
guidelines on animal care of the Federal University of Sergipe Ethics Committee for Animal 
Use in Research (CEPA/UFS # 16/12), which was conducted in accordance with the 
internationally accepted principles for laboratory animal use and care. The mice submitted to 
intraperitoneally (i.p.) administration of drugs fasted for 12 h before the experiments and 
were acclimatized for at least 2 h before the experiments. All efforts were made to minimize 
the number of animals used and their suffering. The tests were conducted in a blind manner. 
 
Acetic acid-induced writhing 
This test was run using the methods described Koster et al. (1959) and Le Bars et al. (2001).  
Muscular contractions were induced by intraperitoneal injection (i.p.) of a 0.65% solution of 
acetic acid (0.25 ml/animal) in a group of 8 mice (per group).  The number of muscular 
contractions was counted for 15 min after the injection and the data represent the average of 
the total number of writhes observed.  Mice received treatment with essential oil (EO: 25, 50 
and 100 mg/kg, i.p.), sulcatyl acetate (SA: 25 and 50 mg/kg, i.p.) or morphine (MOR: 5 
mg/kg, i.p.), which were solubilized in saline + 0.2% of Tween 80 (vehicle). Control group 
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received only vehicle. All drugs were administered intraperitonealy in different groups of 
mice 1 h before the acetic acid injection. 
 
Formalin test 
The observation chamber was a glass box of 30 cm in diameter on an acrylic transparent 
plate floor.  Beneath the floor, a mirror was mounted at a 45° angle to allow clear 
observation of the paws of the animals.  Mice were treated with the vehicle (saline + 0.2% of 
Tween 80), EO (25, 50 and 100 mg/kg, i.p.), SA (25 and 50 mg/kg, i.p.), or acetylsalicylic 
acid (ASA 200 mg/kg, i.p.) 1 h before the formalin injection.  Each mouse was placed in the 
chamber more than 5 min before treatment in order to allow acclimatization to the new 
environment.  The formalin test was carried out as described by Hunskaar and Hole (1987).  
Twenty microliters of a 2.5% formalin solution in a phosphate-buffer were injected into the 
dorsal surface of the left hind paw using a microsyringe with a 26-gauge needle.  Each 
animal was then returned to the chamber and the amount of time that the animal spent 
licking the injected paw was considered to be indicative of nociception.  Two distinct phases 
of intensive licking activity were identified:  an early acute phase and a late or tonic phase (0-
5 and 15-30 min after formalin injection, respectively). 
 
Evaluation of the motor activity 
In order to evaluate a possible non-specific muscle-relaxant or sedative effect of the EO or 
SA, mice were submitted to the rota-rod test, according to what had been described by 
Quintans-Júnior et al. (2010). Initially, the mice able to remain on the Rota-rod apparatus 
(AVS®, Brazil) longer than 180 s (9 rpm) were selected 24 h before the test. Mice were 
treated with EO (25, 50 and 100 mg/kg, i.p.) or SA (25 and 50 mg/kg, i.p.), vehicle or 
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diazepam (3 mg/kg, i.p.) 1, 2 and 4h before evoluation on Rota-rod apparatus. E each 
animal remained on the bar for up to 180 s.  
 
Statistical analysis 
Data obtained from animal experiments were expressed as mean and standard error of the 
mean (mean ± S.E.M.). Statistical differences between the treated and the control groups 
were evaluated by ANOVA followed by Dunnett‟s test. Differences were considered to be 
statistically significant when p < 0.05. All statistical analyses were performed using Graph 
Pad Prism 5 (Graph Pad Prism Software Inc., San Diego, CA, USA). 
 
Results and Discussion 
In the present study, we evaluated the antinociceptive activity of the A. trilobata 
essential oil (EO) and of the A. trilobata majoritary compound 6-methyl-5-hepten-2yl acetate 
(sulcatyl acetate, SA), both in male mice.  
According to Santos et al. (Santos et al., 2014), our sample of the essential oil of A. 
trilobata presented an average yield of 0.22 ± 0.05% (v/w), and is composed mainly by 6-
methyl-5-hepten-2-yl acetate (sulcatyl acetate) (21.49 ± 0.43%), germacrene D (15.07 ± 
0.23%), bicyclogermacrene (8.84 ± 0.45%), linalool (6.85 ± 0.42%), (E)-caryophyllene (5.58 
± 0.12%), (E)-β-ocimene (5.56 ± 0.067%) and p-cimene (4.68 ± 0.10%). 
In the pretreatment with EO or SA, all doses significantly (p < 0.001) reduced the 
number of writhing movements (nociceptive behavior) induced by acetic acid solution (Fig 1).  
As expected, morphine (5 mg/kg, i.p.), an opioid analgesic drug, produces an inhibition of 
nociceptive behavior (p < 0.001). In this model, pain is elicited by the injection of an irritant 
such as acetic acid into the peritoneal cavity, which produces episodes of characteristic 
stretching (writhing) movements, and inhibition of the number of episodes by analgesics is 
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easily quantifiable. Despite being a non-specific test, acetic acid-induced writhings are a 
highly sensitive and useful test for analgesic drug development (Le Bars et al., 2001). 
 
INSERT FIGURE 1 
 
After the antinociceptive effects of EO and SA were evaluated in a model of 
persistent nociception, the formalin test, which has two distinctive phases that can possibly 
indicate different types of pain (Hunskaar and Hole, 1987). The early and late phases of 
formalin test have obvious differential properties, and therefore this test is useful not only for 
assessing the analgesic substances but also for an initial investigation the mechanism of 
analgesia (Shibata et al., 1989). The early phase, named non-inflammatory pain, is a result 
of direct stimulation of nociceptors and reflects centrally mediated pain; the late phase, 
named inflammatory pain, is caused by local inflammation with a release of inflammatory 
and hyperalgesic mediators (Hunskaar and Hole, 1987). In the present study, we found that 
EO and SA produced antinociceptive activity both in the early (p < 0.05) and late (p < 0.05-
0.001) phases of formalin test (Fig 2). However, EO was effective in the early phase only in 
higher dose (p < 0.05).  
 
INSERT FIGURE 2 
 
Several studies have shown the antinociceptive and anti-inflammatory effects of 
terpenes or essential oils, as reviewed by Almeida et al. (2001), Da Silveira e Sá et al. 
(2013), De Sousa (2011) and Guimarães et al. (2013). Studies performed with linalool and p-
cymene, major compounds found in EO of A. trilobata, demonstrated the antinociceptive 
13 
 
activity of these monoterpenes in different experimental models of nociception (Batista et al., 
2010; Menezes et al., 2014; Quintans et al., 2013; Quintans-Júnior et al., 2013; Santana et 
al., 2011). Furthermore, the major compound, which has its pharmacological activity 
described for the first time in this study, can act synergistically with these compounds thus 
contributing to the pharmacologic response observed.This therapeutic property has gained 
prominence among research groups of academic community and industry, which increased 
interest in developing new options for pain management. Furthermore, the high market 
acceptance of drugs containing terpenes and essential oils for pain control, such as 
Acheflan® and Salompas® motivate further research in this area and has led to an increase 
in patent filings in several countries (Guimarães et al., 2014). 
Previous studies suggested that the CNS depression and the nonspecific muscle 
relaxation effect can reduce the response of motor coordination and might invalidate the 
behavior tests results (Quintans-Júnior et al., 2010). We observed that EO or SA-treated 
mice did not show any significant motor performance alterations with all doses tested (data 
not shown). Thus, we refute the hypothesis of a possible relaxing or motor deficit effects of 
EO and SA at the therapeutic doses.  
Together, our results suggest that EO and sulcatyl acetate, its main compound, 
modulates neurogenic and inflammatory pain in the tests used (Fig 3). Thus, it was observed 
that the sulcatyl acetate is responsible, at least in part, for the analgesic profile of this 
essential oil. The antinociceptive actions demonstrated in A. trilobata in this study support 
the ethnomedicinal use of this plant. More studies are needed to determine the ED50 and 
the dose conversion ratio (DCR) of compounds with standard drugs. 
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FIGURE LEGENDS  
 
Figure 1: Effects of EO or SA on the acetic acid-induced writhing test in mice. Vehicle 
(control), EO (25, 50 or 100 mg/kg), SA (25 or 50 mg/kg) or morphine (MOR, 5 mg/kg) were 
administered i.p. 1 hr before acetic acid injection. Each column represents mean ± S.E.M. (n 
= 8, per group). ***p < 0.001 versus control (ANOVA followed  y Dunnett‟s test). 
 
Figure 2: Effects of EO or SA on the formalin-induced nociception in mice. Vehicle (control), 
EO (25, 50 and 100 mg/kg), SA (25 or 50 mg/kg) or aspirin (200 mg/kg) were administered 
i.p. 1 h before formalin injection. (A) Represents the first phase and (B) represents second 
phase of formalin-induced nociception in mice. Each column represents mean ± S.E.M. (n = 
8, per group). *p < 0.05, **p < 0.01 or ***p < 0.001 versus control (ANOVA followed by 
Dunnett‟s test). 
 
Figure 3: Summary of the data obtained. 
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cover letter should not extend 200 words. 
Contributions submitted to this journal must be written in clear and concise English. Only 
unpublished material can be accepted, and authors may not re‐publish a previously published paper 
(print version or online) in the same or similar form. The decision on the acceptance is taken after a 
peer‐reviewing procedure.  
Please upload a PDF file of the entire paper for the review process (file designation: Main document) 
and additionally a full set of original files as ZIP archive (file designation: Source Codes (tex, cls, sty 
etc.) as ZIP archive). Please include the ChemDraw files of your chemical structure drawings in the ZIP 
archive. Do not include the figures in a Word document. 
The authors are strongly encouraged to suggest at least two names, institutional affiliation and e‐
mail addresses of potential independent reviewers. 
Manuscript preparation 
Order of the text: Running title (maximal 60 characters) – Title (Title and running title: first characters 
should not be capitalized). Authors‘ names (e.g. Jan Baier, Tom F. Miller, and John F. Kelly) – First 
author‘s address (and under 1, 2, 3 ... differing addresses of further authors; the corresponding author 
should be indicated by * in the list of authors, and his/her e‐mail address should be provided.) – 
Dedication (if intended) – Abstract – Keywords (at most five). 
Following the main text: Acknowledgements (if wished) – List of references – Footnotes – Tables with 
captions (each table on a separate page) – List of all figure legends – Figures (uploaded as separate 
files). 
 
 Nomenclature 
Biochemical: As far as possible authors should follow the recommendations of the Nomenclature 
Committee of IUBMB and the IUPAC–IUBMB Joint Commission on Biochemical Nomenclature 
(see http://www.chem.qmul.ac.uk/iubmb/). 
Chemical: The IUPAC recommendations on chemical nomenclature (see 
http://www.chem.qmul.ac.uk/iupac/index.html) should be followed. 
Enzymes: The recommendations of the latest edition of Enzyme Nomenclature (see 
http://www.chem.qmul.ac.uk/iubmb/enzyme, 1992) should be followed as far as possible. This 
includes the quoting of EC numbers. 
Scientific names of organisms should be cited in their complete form when first mentioned in the 
order genus ‐ species ‐ authority ‐ cultivar (cv.) or subspecies (ssp.) where appropriate. Latin genus 
and species names should be typed in italics. Subsequently, the genera should generally be 
abbreviated by their first letter, but avoid confusion: e.g. use A. comosus if the only genus with the 
first letter A in your manuscript is Ananas; but use unambiguous abbreviations if there is more than 
one genus with the same first letter, e.g. Ananas comosus, Aechmea nudicaulis = A. comosus, Ae. 
nudicaulis, etc. Common names of organisms must be accompanied by the correct scientific name 
when first mentioned. It may be useful to give the name of the family and/or higher taxon in brackets 
when first mentioned. 
Compound Characterization Data  
A Journal of Biosciences: Zeitschrift für Naturforschung C holds a high standard for compound 
characterization. For new compounds, evidence for identity and purity must be provided. Evidence 
for documenting the identity of new compounds should include proton and carbon NMR data and 
MS accurate mass (HRMS) or elemental analysis data. A copy of a spectrum with a signal‐to‐noise 
ratio sufficient to permit seeing peaks with 5% of the intensity of the strongest peak should be 
included in the supporting information.  
When new or known compounds are used for bioassays, a purity level of at least 95% needs to be 
documented. Evidence for documenting compound purity should include proton and carbon NMR 
spectraand be included in the supporting information. 
Tables, equations and figures are to be mentioned in the text in numerical order (Table 1, Fig. 1, etc.). 
Only equations should be integrated in the intended place in the text. Figures in high resolution (300 
dpi) should be uploaded as separate files.  
The abstract must be suitable for direct use by the abstracting journals. 
The main text should meet the highest standard as to organization and conciseness, and should be 
correct in orthography, grammar and style. 
References must be numbered consecutively by order of mention in the text , e.g. [1], [2,3], [7‐10], 
etc., and listed according to the following examples for journals and books, respectively. Abbreviate 
journal names according to the PubMed Journals Database (National Library of Medicine, National 
Institutes of Health; http://www.ncbi.nlm.nih.gov/pubmed). One‐word journal names (e.g., 
Biochemistry) are never abbreviated. In multi‐author references, use “et al.” after the sixth author.  
 
 Examples for journal references: 
1. Raad II, Hanna HA, Hachem RY, Dvorak T, Arbuckle RB, Chaiban G, et al. Clinical‐use‐ associated 
decrease in susceptibility of  vancomycin‐resistant Enterococcus faecium to linezolid: a 
comparison with quinupristin‐dalfopristin. Antimicrob Agents Chemother 2004;48:3583–5. 
2. Wells D, Bjorksten A. Monoamine oxidase inhibitors revisited. Can J Anaesth 1989;36:64–74. 
3. Parsons MR, Convery MA, Wilmot CM, Yadavt KD, Blakeley V, Corner AS, et al. Crystal structure 
of a quinoenzyme: copper amine oxidase of Escherichia coli at 2 A resolution. Structure 
1995;3:1171–84. 
Examples for book references: 
1. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3rd ed. New York: Cold Spring 
Harbour Laboratory Press, 2001. 
2. Gower JC, Lubbe S, le Roux NJ. Understanding biplots. Chichester, UK: Wiley, 2011. 
3. Moss JN, Dajani E. Antihyperlipidemic agents. In: Turner RA, Hebborn P, editors. Screening 
methods in toxicology. New York: Academic Press, Vol. 2, 1971:121.  
Illustrations (figures) should be of reproducible quality. They will be reduced in size to fit, whenever 
possible, the width of a single column. Lettering of all figures within the article should be uniform in 
style and of sufficient size (ca. 10 pt). Uppercase letters A, B, C, etc. should be used to identify parts 
of multi‐part figures. In the legend, these letters are included in parentheses. Cite all figures in the 
text in numerical order. Micrographs should contain a size bar. Indicate the approximate placement 
of each figure. Do not embed figures within the text body of the manuscript; submit figures in 
separate files. Really necessary colour figures will be printed free of charge. 
Chemical Structures should be produced with the use of a drawing program such as ChemDraw. 
Structure drawing preferences (preset in ChemDraw from the “File” menu, choose “Apply document 
settings from ACS Document 1996”) are as follows:  
1. As drawing settings select: chain angle 120°; bond spacing 18% of width; fixed length 14.4 pt 
(0.508 cm, 0.2 in.); bold width 2.0 pt (0.071 cm, 0.0278 in.); line width 0.6 pt (0.021 cm, 0.0084 
in.); margin width 1.6 pt (0.056 cm, 0.0222 in.); hash spacing 2.5 pt (0.088 cm, 0.0347 in.) 
2. As text settings select: font Arial/Helvetica; size 10 pt. 
3. Under the preferences choose: units points tolerances 5 pixels. 
4. Under page setup choose: Paper US Letter; scale 100%. 
Additional tables, figures, videos, appendices, etc. can be submitted as Supplementary Material for 
online only publication. Supplementary Material data should be submitted as separate file(s) during 
submission. Within the text, Supplementary Material must be cited consecutively and be referred to 
as Supplementary Material data (e.g, see Supplementary Material, Fig. 1). If the manuscript is 
accepted and the Supplementary Material is posted online, it will be referenced in the printed 
version. 
The authors will receive page proofs electronically. Please note that corrections should be restricted 
to typographical errors. Cost for extensive additional changes will be charged to the authors. 
Changes in the text and in the illustrations after acceptance of the manuscript cause delay and create 
extra cost which may be charged to the author. 
 
 
 For authors interested in open access publication 
If your manuscript is accepted, open access publication is available for the A Journal of Biosciences: 
Zeitschrift für Naturforschung C (ZNC) authors who wish to make their article freely available on De 
Gruyter Online. Authors choosing to publish open access pay an article processing charge. Choosing 
open access publication has no influence on the peer review or acceptance process. 
For more information on De Gruyter’s open access policies and charges please visit: 
http://www.degruyter.com/page/560 
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